• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2-硫代嘧啶/查尔酮杂合体的设计、合成、ADMET 预测和作为 STAT3/STAT5a 抑制剂的抗癌评估。

2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.

机构信息

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.

出版信息

J Enzyme Inhib Med Chem. 2020 Dec;35(1):864-879. doi: 10.1080/14756366.2020.1740922.

DOI:10.1080/14756366.2020.1740922
PMID:32208772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7144330/
Abstract

A novel 2-thiopyrimidine/chalcone hybrid was designed, synthesised, and evaluated for their cytotoxic activities against three different cell lines, K-562, MCF-7, and HT-29. The most active cytotoxic derivatives were , , , and (IC=0.77-1.74 µM, against K-562 cell line), and (IC=1.37-3.56 µM against MCF-7 cell line), and , , and (IC=2.10 and 2.37 µM against HT-29 cell line). Compounds , , , , and were further evaluated for their cytotoxicity against normal fibroblast cell line WI38. Moreover, STAT3 and STAT5a inhibitory activities were determined for the most active derivatives , , , , and . Dual inhibitory activity was observed in compound (IC=113.31 and 50.75 µM, against STAT3 and STAT5a, respectively). Prediction of physicochemical properties, drug likeness score, pharmacokinetic and toxic properties was detected.

摘要

设计、合成了一种新型的 2-嘧啶/查尔酮杂合体,并对其在三种不同细胞系(K-562、MCF-7 和 HT-29)中的细胞毒性进行了评价。最具活性的细胞毒性衍生物为 、 、 和 (IC=0.77-1.74µM,针对 K-562 细胞系)、 和 (IC=1.37-3.56µM,针对 MCF-7 细胞系)以及 、 、 和 (IC=2.10 和 2.37µM,针对 HT-29 细胞系)。进一步对化合物 、 、 、 和 进行了针对正常成纤维细胞系 WI38 的细胞毒性评价。此外,还对最具活性的衍生物 、 、 、 和 进行了 STAT3 和 STAT5a 抑制活性的测定。在化合物 (IC=113.31 和 50.75µM,针对 STAT3 和 STAT5a,分别)中观察到双重抑制活性。还检测了预测的物理化学性质、药物相似性评分、药代动力学和毒性特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/c4afb7647125/IENZ_A_1740922_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/9bebd4b20ab0/IENZ_A_1740922_UF0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/4c08d9b4d719/IENZ_A_1740922_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/7813845591d4/IENZ_A_1740922_SCH0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/63f171133417/IENZ_A_1740922_SCH0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/dae53faced97/IENZ_A_1740922_SCH0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/4db434557133/IENZ_A_1740922_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/60f1e034005a/IENZ_A_1740922_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/c4afb7647125/IENZ_A_1740922_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/9bebd4b20ab0/IENZ_A_1740922_UF0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/4c08d9b4d719/IENZ_A_1740922_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/7813845591d4/IENZ_A_1740922_SCH0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/63f171133417/IENZ_A_1740922_SCH0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/dae53faced97/IENZ_A_1740922_SCH0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/4db434557133/IENZ_A_1740922_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/60f1e034005a/IENZ_A_1740922_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d91/7144330/c4afb7647125/IENZ_A_1740922_F0004_C.jpg

相似文献

1
2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.2-硫代嘧啶/查尔酮杂合体的设计、合成、ADMET 预测和作为 STAT3/STAT5a 抑制剂的抗癌评估。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):864-879. doi: 10.1080/14756366.2020.1740922.
2
1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.1,3,4-噁二唑/查尔酮杂合体的设计、合成及对白血病细胞生长和 EGFR、Src、IL-6 和 STAT3 活性的抑制作用。
Bioorg Chem. 2019 Mar;84:150-163. doi: 10.1016/j.bioorg.2018.11.032. Epub 2018 Nov 22.
3
Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF kinases.设计并合成新型喹啉/查尔酮/1,2,4-三唑杂合体作为针对 EGFR 和 BRAF 激酶的有效增殖抑制剂。
Bioorg Chem. 2021 Jan;106:104510. doi: 10.1016/j.bioorg.2020.104510. Epub 2020 Nov 24.
4
Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors.新型吲哚/1,2,4-三唑/查尔酮杂合体的设计、合成及作为 EGFR 和/或 c-MET 抑制剂的抗增殖活性。
Arch Pharm (Weinheim). 2024 Sep;357(9):e2300562. doi: 10.1002/ardp.202300562. Epub 2024 Jun 21.
5
Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.新型3,6-二甲基-1-苯基-4-(取代甲氧基)吡唑并[3,4-d]嘧啶衍生物的合成、表皮生长因子受体抑制作用及抗癌活性
Anticancer Agents Med Chem. 2017;17(10):1389-1400. doi: 10.2174/1872211311666170213105004.
6
Application of the dual-tail approach for the design and synthesis of novel Thiopyrimidine-Benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors.双尾法在新型噻二嗪-苯磺酰胺杂合体的设计与合成中的应用,作为选择性碳酸酐酶抑制剂。
Eur J Med Chem. 2022 Jan 15;228:114004. doi: 10.1016/j.ejmech.2021.114004. Epub 2021 Nov 20.
7
Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.新型吡唑查尔酮洛索洛芬类似物的设计、合成及分子对接作为潜在的抗癌和抗炎活性的 5-脂氧合酶、诱导型一氧化氮合酶和微管蛋白聚合抑制剂。
Bioorg Chem. 2022 Dec;129:106171. doi: 10.1016/j.bioorg.2022.106171. Epub 2022 Sep 22.
8
Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.靶向VEGFR-2酶的新型三唑并[3,4-a]酞嗪衍生物的设计、合成、体外抗癌活性、ADMET特性及分子对接
Anticancer Agents Med Chem. 2018;18(8):1184-1196. doi: 10.2174/1871520618666180412123833.
9
Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors.新型咪唑查尔酮衍生物的设计、合成及作为潜在抗癌剂和微管蛋白聚合抑制剂的生物评价。
Bioorg Chem. 2021 Jul;112:104904. doi: 10.1016/j.bioorg.2021.104904. Epub 2021 Apr 20.
10
New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.新型噻吩并[3,2-d]嘧啶衍生物的设计、合成与生物评价:作为抗增殖剂、EGFR 和 ARO 抑制剂诱导乳腺癌细胞凋亡。
Bioorg Chem. 2021 Oct;115:105208. doi: 10.1016/j.bioorg.2021.105208. Epub 2021 Jul 26.

引用本文的文献

1
Amide linked chalcone derivatives, a promising class of compounds with versatile biological effects.酰胺连接的查尔酮衍生物,一类具有多种生物效应的有前景的化合物。
RSC Adv. 2025 Jun 5;15(24):19043-19068. doi: 10.1039/d5ra00834d. eCollection 2025 Jun 4.
2
Identification of chalcone analogues as anti-inflammatory agents through the regulation of NF-κB and JNK activation.通过调节NF-κB和JNK激活来鉴定查尔酮类似物作为抗炎剂
RSC Med Chem. 2024 Apr 4;15(6):2002-2017. doi: 10.1039/d4md00011k. eCollection 2024 Jun 19.
3
Targeting STAT3 and NF-κB Signaling Pathways in Cancer Prevention and Treatment: The Role of Chalcones.

本文引用的文献

1
Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents.设计和合成新型苯并恶唑/苯并噻唑-邻苯二甲酰亚胺杂合体作为抗肿瘤凋亡试剂。
Bioorg Chem. 2019 Aug;89:102978. doi: 10.1016/j.bioorg.2019.102978. Epub 2019 May 10.
2
1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.1,3,4-噁二唑/查尔酮杂合体的设计、合成及对白血病细胞生长和 EGFR、Src、IL-6 和 STAT3 活性的抑制作用。
Bioorg Chem. 2019 Mar;84:150-163. doi: 10.1016/j.bioorg.2018.11.032. Epub 2018 Nov 22.
3
STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context.
靶向STAT3和NF-κB信号通路在癌症预防和治疗中的作用:查耳酮的作用
Cancers (Basel). 2024 Mar 8;16(6):1092. doi: 10.3390/cancers16061092.
4
Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents-In Vitro Evaluation against Breast Cancer Cells.4-酰基-1-苯氨基羰基-2-取代哌嗪衍生物的再利用研究作为潜在的抗癌药物-体外评估对乳腺癌细胞的作用。
Int J Mol Sci. 2023 Dec 1;24(23):17041. doi: 10.3390/ijms242317041.
5
Design, synthesis, and anti-hepatocellular carcinoma of thiopyrimidine/chalcone hybrids as dual STAT3/STAT5 inhibitors.作为双STAT3/STAT5抑制剂的硫代嘧啶/查尔酮杂合物的设计、合成及抗肝细胞癌活性
RSC Med Chem. 2023 Aug 15;14(10):1981-1991. doi: 10.1039/d3md00300k. eCollection 2023 Oct 18.
6
Anticancer Cytotoxic Activity of Bispidine Derivatives Associated with the Increasing Catabolism of Polyamines.双哌啶衍生物与多胺分解代谢增加相关的抗癌细胞毒性活性。
Molecules. 2022 Jun 16;27(12):3872. doi: 10.3390/molecules27123872.
7
Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines.新型查尔酮-噻吩嘧啶衍生物在 HepG2 和 MCF-7 细胞系中的合成、抗癌评估和分子对接。
Oxid Med Cell Longev. 2021 Dec 28;2021:4759821. doi: 10.1155/2021/4759821. eCollection 2021.
8
Novel chalcone/aryl carboximidamide hybrids as potent anti-inflammatory via inhibition of prostaglandin E2 and inducible NO synthase activities: design, synthesis, molecular docking studies and ADMET prediction.新型查尔酮/芳基甲脒类杂合物通过抑制前列腺素 E2 和诱导型一氧化氮合酶活性发挥强效抗炎作用:设计、合成、分子对接研究和 ADMET 预测。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1067-1078. doi: 10.1080/14756366.2021.1929201.
9
Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.发现具有口服活性的查耳酮作为组蛋白赖氨酸特异性去甲基化酶 1 抑制剂用于治疗白血病。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):207-217. doi: 10.1080/14756366.2020.1852556.
STAT3 在乳腺癌发生和进展中的作用:时间和环境的问题。
Int J Mol Sci. 2018 Sep 18;19(9):2818. doi: 10.3390/ijms19092818.
4
Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-]pyrimidines as potential anticancer agents.查尔酮连接的吡唑并[1,5 -]嘧啶作为潜在抗癌剂的合成与生物学评价
Medchemcomm. 2017 Jul 13;8(9):1810-1816. doi: 10.1039/c7md00193b. eCollection 2017 Sep 1.
5
New 1,2,4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells.新型 1,2,4-三唑查尔酮杂合体诱导 A549 人肺腺癌细胞 Caspase-3 依赖性细胞凋亡。
Eur J Med Chem. 2018 May 10;151:705-722. doi: 10.1016/j.ejmech.2018.03.073. Epub 2018 Mar 27.
6
Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment.抵抗是徒劳的:针对线粒体能量和代谢来克服癌症治疗中的耐药性。
Cell Metab. 2017 Nov 7;26(5):705-707. doi: 10.1016/j.cmet.2017.10.013.
7
Design, synthesis and antimicrobial evaluation of pyrimidin-2-ol/thiol/amine analogues.嘧啶 -2-醇/硫醇/胺类似物的设计、合成及抗菌活性评价
Chem Cent J. 2017 Jun 9;11(1):52. doi: 10.1186/s13065-017-0284-2.
8
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.联合靶向 STAT3 和 STAT5:克服慢性髓性白血病耐药性的新方法。
Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.
9
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.结直肠癌:结直肠癌的概述与未来展望
Int J Mol Sci. 2017 Jan 19;18(1):197. doi: 10.3390/ijms18010197.
10
Cytotoxic Evaluation against Breast Cancer Cells of Isoliquiritigenin Analogues from Spatholobus suberectus and Their Synthetic Derivatives.鸡血藤异甘草素类似物及其合成衍生物对乳腺癌细胞的细胞毒性评价
J Nat Prod. 2016 Jan 22;79(1):248-51. doi: 10.1021/acs.jnatprod.5b00774. Epub 2015 Dec 21.